Is BPC-157 legal in the US?
Approval, a prescribing decision and compounding authority each answer a different question. The withdrawn nomination deserves a careful entry.
FDA approval
FDA has not approved a finished BPC-157 drug. Prescription care involves a licensed prescriber's decision about an individual; a compounded product carries no FDA approval. The 2025 clinical review treats BPC-157 as investigational, with limited human data and unresolved safety questions.
I attach less weight to the reassuring sound of prescribed than to the record supporting a particular decision. A valid prescription and a pharmacy's authority to use a bulk ingredient are separate questions under the FDA compounding documents. The individual review cannot erase an ingredient requirement.
The withdrawn BPC-157 nomination
FDA originally placed BPC-157 in Category 2, the group for nominated bulk substances that may present significant safety risks. The concerns covered potential immune reactions and difficulties with purity and characterisation, including BPC-157 and BPC-157 acetate. The FDA safety-risk page records those concerns.
BPC-157 appears in FDA's table of nominations withdrawn from review, separate from the active Category 2 table. The page says the nominator withdrew the request; it does not identify that party or give a reason.
Withdrawal leaves the safety concerns on record and supplies no FDA authorisation to compound BPC-157. I think this is the easiest entry to misread: a changed place in a table can look like a favourable verdict. The documented action is withdrawal of a nomination. Approval and lawful compounding require their own authority.
Section 503A and bulk ingredients
Section 503A concerns compounding by a state-licensed pharmacy or physician, generally for an individual with a valid prescription. FDA-registered outsourcing facilities operate under a separate set of requirements. Both have obligations concerning the ingredients they use, as described in the FDA's compounding documents.
For the 503A bulk-substance question, the routes include an applicable official compendial standard, a component of an FDA-approved drug, or inclusion on FDA's permitted list. A nomination for review alone does not satisfy every requirement.
Under the earlier interim policy, Category 1 and Category 2 carried different enforcement positions. On January 7, 2025, FDA ended that sorting for new nominations. That action left the earlier safety concern intact. The withdrawn BPC-157 request supplies no new compounding permission.
Prescriber review and pharmacy review
A licensed prescriber evaluates an individual's needs and may decline a request. A pharmacy then has its own responsibility to determine whether it can prepare or dispense the medicine under applicable requirements. State rules and the treatment being considered affect the options.
A video visit still requires a proper clinical evaluation. The form of the visit changes neither the bulk-ingredient rules nor the product's approval status. I prefer an access explanation that names the separate decisions, because a single yes to prescription can obscure the pharmacy question. The FDA source list supplies the background to those requirements.
May a pharmacy make BPC-157 for you now?
Promise Peptides has begun prescribing BPC-157 as prescription-required care at mypromise.com. A licensed clinician in the U.S. reads each case and may decide against prescribing. The service accepts U.S. patients; what it can offer rests on both the patient's state and the particular treatment. A pharmacy-made BPC-157 medicine does not carry FDA approval. FDA records the withdrawn nomination apart from active Category 2 entries and retains its safety concerns [1][2]. A prescription does not settle whether a raw ingredient meets compounding law [1].
The advisory committee record
The FDA agenda lists BPC-157 and BPC-157 acetate for discussion by the Pharmacy Compounding Advisory Committee. That committee advises FDA; FDA makes the final listing decision. The agenda in the regulatory reading list documents the subject for discussion and establishes no final permission by itself.
Possession and competitive sport
The cited FDA pages address approval and compounding. They do not state that merely possessing or personally using BPC-157 is a crime. State rules may differ; these documents cannot answer an individual's entire legal situation.
Competitive sport has a separate rule. The World Anti-Doping Agency prohibits BPC-157 at all times under its non-approved-substances category. A pharmacy question and a sporting prohibition remain separate even when the same peptide name appears in both. This page provides background, not advice for an individual legal case.